References
- 1. Egbuna OI, Brown EM. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol. 2008, 22, 129-148.
- 2. Springhurst FR, Demay MB, Kronenberg HM. Hormones and disorders of mineral metabolism. In: Williams Textbook of Endocrinology. Vol. 1. Kronenberg HM.Melmed S,Polonsky, KS., Larsen PR (editors), Saunders Elsevier, 2008, 1203-1268.
- 3. Silva BC, Costa AG, Cusano NE, et al. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest, 2011, 34, 801-810.
- 4. Balani DH, Ono N, Kronenberg HM. Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest, 2017, 127, 3327-38.
- 5. Fan Y, Hanai JI, Le PT, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab, 2017; 25, 661-72.
- 6. Ishizuya T, Yokose S, Hori M, et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest, 1997, 99 (12), 2961-70.
- 7. Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem, 2003, 278(50), 50259-72.
- 8. Schnoke M, Midura SB, Midura RJ. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone, 2009, 45(3), 590-602.
- 9. Aslan D, Andersen MD, Gede LB, et al. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand J Clin Lab Invest, 2012, 72(1), 14-22.
- 10. Bodine PV, Komm BS. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord, 2006, 7(1-2), 33-39.
- 11. Almeida M, Han L, Bellido T, et al. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and-independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem, 2005, 280(50), 41342-51.
- 12. Bodine PV, Billiard J, Moran RA, at al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem, 2005, 96(6), 1212-30.
- 13. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental cell 2005, 8, 751-764.
- 14. Kulkarni NH, Halladay DL, Miles RR, et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem, 2005, 95(6), 1178-90.
- 15. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology, 2005, 146(11), 4577-83
- 16. Qin L, Qiu P, Wang L, et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem, 2003, 278, 19723-31.
- 17. Kim JH, Kim N. Signaling Pathways in Osteoclast Differentiation. Chonnam Med J, 2016, 52(1), 12-17.
- 18. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89, 309-319.
- 19. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology, 2001, 142, 5050-55.
- 20. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev, 2008, 29, 155-192.
- 21. Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 2001, 142, 4047-54.
- 22. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res, 2004,19, 235-244.
- 23. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone, 2005, 37, 148-58.
- 24. Bonewald LF. The amazing osteocyte. J Bone Miner Res, 2011, 26, 229-38.
- 25. O’Brien CA, Nakashima T, Takayanagi H. Osteocyte control of osteoclastogenesis. Bone, 2013, 54, 258-63.
- 26. van Bezooijen RL, ten Dijke P, Papapoulos SE, et al. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev, 2005, 16, 319-27.
- 27. Ben-awadh AN, Delgado-Calle J, Tu X, et al. Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology, 2014, 155, 2797-809.
- 28. Hory BG, Roussanne MC, Rostand S, et al. Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in culture. J Endocrinol Invest, 2000, 23(5), 273-9.
- 29. Gao Y, Wu X, Terauchi M, et al. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab, 2008, 8(2), 132-45.
- 30. Pacifici R. T cells: critical bone regulators in health and disease. Bone, 2010, 47, 461-471.
- 31. Terauchi M, Li JY, Bedi B, et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab, 2009, 10(3), 229-240.
- 32. D’Amelio P, Sassi F, Buondonno I, et al. Treatment with intermittent PTH increases Wnt10b production by T cells in osteoporotic patients. Osteoporos Int., 2015, 26(12), 2785-91.
- 33. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One, 2010, 5(8), e12290.
- 34. Li JY, D’Amelio P, Robinson J, et al. IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice. Cell Metab, 2015, 22(5), 799-810.
- 35. Tawfeek H, Bedi B, Li JY, et al. Disruption of PTH Receptor 1 in T cells protects against PTH-induced bone loss. PLoS One, 2010, 5, e12290.
- 36. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J. Bone Miner Res, 2006, 21, 171-7.
- 37. Lee JH, Chung SM, Kim HS. Osteitis fibrosa cystica mistaken for malignant disease. Clin Exp Otorhinolaryngol, 2013, 6, 110-3.
- 38. Bandeira F, Cusano NE, Silva BC, et al. Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metabol, 2014, 58, 553-61.
- 39. Marcocci C, Cianferotti L, Cetani F. Bone disease in primary hyperparathyrodism. Ther Adv Musculoskelet Dis, 2012, 4, 357-68.
- 40. Chew FS, Huang-Hellinger F. Brown tumor. Am. J. Roentgen-ol, 1993, 160, 752-752.
- 41. Van der Woude HJ, Smithuis R. Bone tumor – systematic approach and differential diagnosis. Radiologyassistant (2010).
- 42. Selvi F, Cakarer S, Tanakol R, et al. Brown tumor of the maxilla and mandible: a rare complication of tertiary hyperparathyroidism. Dentomaxillofacial Radiol, 2009, 38, 53-58.
- 43. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res, 1989, 4, 283-91.
- 44. Parisien M, Cosman F, Mellish RW, et al. Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res, 1995, 10, 1393-9.
- 45. Lewiecki EM, Miller PD. Skeletal effects of primary hyper-parathyroidism: bone mineral density and fracture risk. J Clin Densitom, 2013, 16, 28-32.
- 46. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab, 2008, 93, 3462-70.
- 47. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab, 2014, 99, 3561-9.
- 48. Silva BC, Boutroy S, Zhang C, et al. Trabecular bone score (TBS) - a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab, 2013, 98, 1963-70.
- 49. Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res, 2013, 28, 1029-40.
- 50. Makras P, Anastasilakis AD. Bone disease in primary hyper-parathyroidism. Metabolism, 2018, 80, 57-65.
- 51. Valdemarsson S, Lindergård B, Tibblin S, et al. Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease. J Intern Med, 1998, 243(2), 115-122.
- 52. Christiansen P, Steiniche T, Brixen K, et al. Primary hyper-parathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone, 1999, 25(2), 237-244.
- 53. Heaney RP. The basis for the post-parathyroidectomy increase in bone mass. J Bone Miner Res, 2002, 17(2), 154-7.
- 54. Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med, 1999, 341(17), 1249-55.
- 55. Silverberg SJ, Locker FG, Bilezikian JP. Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab, 1996 Nov, 81(11), 4007-12.
- 56. Thorsen K, Kristoffersson AO, Lorentzon RP. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery, 1997,122(5), 882-887.
- 57. Steiniche T, Christiansen P, Vesterby A, et al. Primary hyper-parathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment. Bone, 2000, 26(5), 535-543.
- 58. Garton M, Martin J, Stewart A, et al. Changes in bone mass and metabolism after surgery for primary hyperparathyroidism. Clin Endocrinol (Oxf), 1995, 42(5), 493-500.
- 59. Alonso S, Ferrero E, Donat M, et al. The usefulness of high preoperative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy. J Endocrinol Invest, 2012, 35, 640-644.
- 60. Tamura Y, Araki A, Chiba Y, et al. Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study. J Bone Miner Metab, 2007, 25(4), 226-231.
- 61. Vestergaard P. Current pharmacological options for the management of primary hyperparathyroidism. Drugs, 2006, 66, 2189-2207.
- 62. Rossini M, Gatti D, Isaiah G, et al. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyper-parathyroidism. J Bone Min Res, 2001, 16, 113-119.